| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Pathology and Molecular Diagnostics,
* Thoracic Oncology,
and Thoracic Surgery,
Aichi Cancer Center Hospital, Nagoya; and the Division of Molecular Carcinogenesis,
Center for Neural Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
It has been demonstrated that lung cancers, specifically a subset of pulmonary adenocarcinomas, with epidermal growth factor receptor (EGFR) mutation are highly sensitive to EGFR-targeted drugs. Therefore, a rapid, sensitive assay for mutation detection using routine pathological specimens is demanded in clinical practice to predict the response. We therefore developed a new assay for detecting EGFR mutation using only a paraffin section of a small biopsy specimen. The method was very sensitive, detecting as few as 5% cancer cells in a background of normal cells, the results usually being obtained within 4 hours. Furthermore, it was accurate, as shown by the high concordance with reverse transcriptase-polymerase chain reaction-coupled direct sequencing (186 of 195, 95%). The practical application of this assay to 29 cases treated with gefitinib resulted in a high prediction rate: 10 of the 11 responders were shown to be positive for the mutation, and all patients with progressive disease were negative. In addition, a mutation at codon 790, conferring gefitinib resistance, was successfully analyzed in a similar manner. In conclusion, the assay is a rapid, sensitive method using paraffin sections of biopsy specimens without a tumor cell-enrichment procedure and is quite useful to select a treatment of choice in clinical practice.
This article has been cited by other articles:
 |
|
 |
|
  A. Tatematsu, J. Shimizu, Y. Murakami, Y. Horio, S. Nakamura, T. Hida, T. Mitsudomi, and Y. Yatabe Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6092 - 6096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukui, Y. Ohe, K. Tsuta, K. Furuta, H. Sakamoto, T. Takano, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, et al. Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2008; 14(15): 4751 - 4757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yatabe, T. Takahashi, and T. Mitsudomi Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer Cancer Res., April 1, 2008; 68(7): 2106 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takano, Y. Ohe, K. Tsuta, T. Fukui, H. Sakamoto, T. Yoshida, U. Tateishi, H. Nokihara, N. Yamamoto, I. Sekine, et al. Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non Small Cell Lung Cancer Treated with Gefitinib Clin. Cancer Res., September 15, 2007; 13(18): 5385 - 5390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Pao and M. Ladanyi Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method Clin. Cancer Res., September 1, 2007; 13(17): 4954 - 4955. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakajima, K. Yasufuku, M. Suzuki, K. Hiroshima, R. Kubo, S. Mohammed, Y. Miyagi, S. Matsukuma, Y. Sekine, and T. Fujisawa Assessment of Epidermal Growth Factor Receptor Mutation by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Chest, August 1, 2007; 132(2): 597 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, and T. Mitsudomi Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res., October 1, 2006; 12(19): 5764 - 5769. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
